"Designing Growth Strategies is in our DNA"
Lymphedema is a condition of an abnormal enlargement of the body associated with lymphostasis from disfunction of the lymphatic system. It usually involves the lower extremity (90%), upper extremity (10%),and genitalia (<1%). The most common cause of lymphedema is the infection due the parasite Wuchereria bancrofti (filariasis). Also lymphedema is one of the most dreaded and undfortunate outcomes of breast cancer treatment. According to article published by National Center for Biotechnology Information (NCBI), in 2014, 40% of the women treated for breast cancer had lymhedma. The lymphedema treatment market growth is driven by the factors such as rising prevalence of lymphedma, growing incidence of breat cancer, various new product launches by key market players, and increasing demands for effcetive products due to growing technological advancements in treatment options. For instance, in August 2018, Sigvaris announced the launch of new accessories and upgrades for their COMPREFLEX REDUCE product portfolio for use during the decongestive phase of lymphedema therapy.
Key Market Driver -
Increasing prevalence of lymphedema, growing incidence of breast cancer
Key Market Restraint -
High cost, lack of reimbursement scenario
The overall lymphedema treatment market is expected to witness significant growth during the forecast period due to factors such as rising prevalence of lymphedema, growing incidence of breast cancer, various new product launches by key market players. However, high cost of the pneumatic compression devices, lack of reimbursement scenario is anticipated to restrict the lymphedema treatment market.
Globally, the lymphedema treatment market can be segmented on the basis of the product type, end-users, and region. Based on the product the market can be segmented into compression bandages, compression stockings, pneumatic compression devices, and others. Based on the end-users, the market can be segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. Geographically, the lymphedema treatment market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
Some of the major companies that are present in the lymphedema treatment market are Bio Compression Systems, Inc., BSN medical, a Lohmann & Rauscher GmbH & Co. KG, SIGVARIS GROUP, Tactile Medical and other prominent players.
Geographically, the lymphedema treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is likely to dominate the lymphedema treatment market. The dominance is owing to the rising prevalence of lymphedema in the region, the growth of which is attributed to the increasing prevalence of breast cancer. For instance, according to the Lymphatic Education & Research Network, approximately 10 million Americans suffer from lymphedema and lymphatic diseases. More people suffer from these diseases in the United States than suffer from multiple sclerosis, muscular dystrophy, Parkinson’s disease, and AIDS -- combined. Europe is projected to hold second largest market share throughout the forecast period. The development of new products and partnership activities of major market players is likely to boost the growth of the lymphedema treatment market in this region. Along with this, the rising prevalence of lymphedema also drives the growth of market in this region. For instance, according to NHS, about 200,000 suffer from lymphedema in U.K. annually. However, Asia Pacific is expected to grow with the highest CAGR due to an increasing incidence of breast cancer and growing patient awareness regarding the lymphedema treatment.
To gain extensive insights into the market, Request for Customization
On the other hand, the market in Latin America and the Middle East & Africa is anticipated to have a substantial market growth during the forecast period owing to the rising patient demand for pneumatic compression devices and compression stockings due to increasing prevalence of the disease.
ATTRIBUTE | DETAILS |
By Product |
|
By End-user |
|
By Geography |
|
US +1 833 909 2966 ( Toll Free )